

Announcement of the license agreement granting SEPPIC the world-wide exclusive rights to  
manufacture and sell the compact automatic emulsion-preparing devices

OncoTherapy Science, Inc. (hereinafter, “OncoTherapy”) announces that OncoTherapy and SEPPIC (Société d'Exploitation de Produits pour les Industries Chimiques) S.A. (hereinafter, “SEPPIC”) agreed that OncoTherapy grants the world-wide exclusive rights to manufacture and sell the compact automatic emulsion-preparing devices originally developed by OncoTherapy, and executed the license agreement, under following conditions:

1. OncoTherapy grants SEPPIC the world-wide exclusive rights to manufacture and sell the compact automatic emulsion-preparing devices.
2. OncoTherapy will provide necessary information for such manufacture and sale to SEPPIC, and cooperate with SEPPIC.
3. OncoTherapy will receive royalty based on the sales amount of such devices in consideration of the licenses under this agreement.

As to the impact of fiscal 2013 full-year forecasts, after carefully reviewing results of this agreement, OncoTherapy will disclose a revised forecast soon in case of necessity. At present, the impact of this license agreement on our consolidated business performance is immaterial.

< Compact Automatic Emulsion-Preparing Device >

Recently, developments of peptide-based cancer vaccines are being accelerated globally. Compact Automatic Emulsion-Preparing Device developed by OncoTherapy is a device for preparation of emulsion by automatically agitating peptide solution and an adjuvant\* in syringes. This device is useful for the relief in preparation work of emulsion in hospitals as compared to conventional manual preparation and the standardization of emulsion.

\*Adjuvant: a pharmacological agent that is administered with an antigen (e.g., peptide) for increasing immunogenicity of the antigen.

< SEPPIC (Société d'Exploitation de Produits pour les Industries Chimiques) S.A. >

Subsidiary of the Air Liquide group within the Healthcare activity, SEPPIC develops and markets a wide range of speciality ingredients for healthcare - excipients and active ingredients - dedicated to the cosmetic, pharmaceutical and vaccine markets. Present in over 70 countries through its subsidiaries and its distribution network, SEPPIC employs over 600 people around the world, including 100 researchers.

Air Liquide's Healthcare World Business Line supplies medical gases, home healthcare services, hygiene products, medical equipment, and specialty ingredients. In 2012, it served over 7,500 hospitals and 1 million patients at home throughout the world. The Group's Healthcare business line also reached €2,482 million in revenues in 2012, with 10,000 employees.